A smart monitor company that received FDA approval in 2015 has seen a five-year stock performance that has outperformed the returns of Apple Inc AAPL, Alphabet Inc GOOGGOOGL and Amazon.com, Inc. AMZN.
The company’s five-year outlook and guidance show that shares could see another strong return in the next five years.
What Happened: In 2015, the FDA approved the DexCom G5, a mobile continuous glucose monitoring (CGM) system. At the time, the device from DexCom, Inc. DXCM was the first and only CGM device approved.
DexCom now competes against others in the CGM field including Abbott Laboratories ABT and Medtronic PLC MDT.
A survey showed the CGM market is expected to grow 38% in 2021 and 29% in 2022 with Dexcom outpacing rivals such as Abbott and Medtronic.
DexCom has been lowering its prices and targeting pharmacies. The company is also planning to launch the G7 CGM by the end of 2021.
In late 2020, DexCom laid out a five-year plan to more than double annual revenue by the year 2025.
The company reported $595 million in second-quarter revenue, up 32% year-over-year. DexCom is guiding for full-year revenue to be in a range of $2.35 billion to $2.4 billion.
Related Link: Moderna And Dexcom Lead The Nasdaq 100
The Five-Year Return: Shares of DexCom are up 489% over the last five years, turning the company into a $50 billion-plus market capitalization company and among the leaders in the diabetes monitoring market.
The return over the past five years from DexCom has outpaced three of the largest technology giants with shares of Apple, Alphabet and Amazon up 473%, 275% and 350%, respectively.
DXCM shares are up 47% year-to-date at the time of writing and trade near a 52-week high of $555.32.
Photo by Thom Holmes on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
